Review and Comparison of sedative effect in using of chloral hydrate and midazolam on children under voiding cystourethrogram

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016041927494N1

Enrollment

150

Registered

2017-03-04

Start date

2016-02-16

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vesico uretro reflux. Congenital vesico-uretero-renal reflux

Interventions

Intervention 1: Without Drug. Intervention 2: Chloralhydrate 0/5 cc/kg. Oral. Singledose. Intervention 3: Midazolam 100/150 mcg/kg. IM. single dosel.

Treatment - Drugs

Without Drug

Chloralhydrate 0/5 cc/kg. Oral. Singledose

Midazolam 100/150 mcg/kg. IM. single dosel

Eligibility

Sex/Gender

All

Age

2 Years to 12 Years

Inclusion criteria

Inclusion criteria: Entrance general conditions to Study: children from 2 - 12 years old both male & female? Children with indication VCUG? children with ASA 1 or 2? obtaining the informed consent from parents or guardian of children To participate in the study Exclusion general conditions from Study: History of systemic chronic diseases such as Renal failure, Respiratory disease and etc? history of narcotic abuse? history sensitivity to midazolam or chloral hydrate? history chronic psychiatric disease including: ADHA, Anxiety, Depression, psychos and Metal retardation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sedation. Timepoint: On time with study. Method of measurement: Visit & question from parents.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Aghagoli

Arak Medical University

aghagoli.mehdi@gmail.com+98 86 3222 4291

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026